Pemigatinib

Catalog No.S0088 Batch:S008801

Technical Data

Formula	C₂₄H₂₇F₂N₅O₄
Molecular Weight	487.50	CAS No.	1513857-77-6
Solubility (25°C)*	In vitro	DMSO	40 mg/mL (82.05 mM)
		Water	Insoluble
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Pemigatinib is an orally active and selective inhibitor of FGFR with IC50 of 0.4 nM, 0.5 nM, 1.2 nM and 30 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.

Targets

FGFR1 ^[1] (Cell-free assay)	FGFR2 ^[1] (Cell-free assay)	FGFR3 ^[1] (Cell-free assay)	FGFR4 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1.2 nM	30 nM

In vitro

Pemigatinib successfully diminishes the capacity of reactive astrocytes to recruit myeloid cells. Potentially FGFR modulation by pemigatinib may be promising for suppression of proinflammatory astrocyte responses while, at the same time, promoting protective mechanisms in murine and human systems.^[2]

In vivo

No effect of pemigatinib on the disease course is evident on acute EAE.^[2]

Protocol (from reference)

Cell Assay:^{^[2]}	Cell lines Primary mouse astrocytes Concentrations 10 μM Incubation Time 24 h Method Primary mouse astrocytes were stimulated with afatinib (10 μM), UNC2025 (10 μM), or pemigatinib (10 μM) for 24 hours. N2A neuronal cells were stimulated with ACM or control medium for 24 hours. Primary mouse astrocytes and N2A neuronal cells were detached and washed once in cold 1× PBS. Live/dead staining was performed. In addition, annexin V–propidium iodide staining was performed. Cells were washed once and resuspended in annexin V binding buffer before acquisition on a 3L Cytek Northern Lights flow cytometer. Analysis of flow cytometry data was performed with the OMIQ platform. (Data sourced from selleck products)
Animal Study:^{^[2]}	Animal Models Female C57Bl/6J mice of experimental autoimmune encephalomyelitis (EAE) model Dosages 2.5 mg/kg Administration i.n. (Data sourced from selleck products)

Cell Assay:^{^[2]}

Cell lines
Primary mouse astrocytes
Concentrations
10 μM
Incubation Time
24 h
Method
Primary mouse astrocytes were stimulated with afatinib (10 μM), UNC2025 (10 μM), or pemigatinib (10 μM) for 24 hours. N2A neuronal cells were stimulated with ACM or control medium for 24 hours. Primary mouse astrocytes and N2A neuronal cells were detached and washed once in cold 1× PBS. Live/dead staining was performed. In addition, annexin V–propidium iodide staining was performed. Cells were washed once and resuspended in annexin V binding buffer before acquisition on a 3L Cytek Northern Lights flow cytometer. Analysis of flow cytometry data was performed with the OMIQ platform.

(Data sourced from selleck products)

Animal Study:^{^[2]}

Animal Models
Female C57Bl/6J mice of experimental autoimmune encephalomyelitis (EAE) model
Dosages
2.5 mg/kg
Administration
i.n.

(Data sourced from selleck products)

References

Selleck's Pemigatinib has been cited by 16 publications

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma [ Nat Commun, 2024, 15(1):3805]	PubMed: 38714664
Chromatin Remodeling in Patient-Derived Colorectal Cancer Models [ Adv Sci (Weinh), 2024, 11(16):e2303379]	PubMed: 38380561
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011]	PubMed: 37377403
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011]	PubMed: 37377403
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer [ Cancer Discov, 2023, 13(9):1998-2011]	PubMed: 37377403
A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma [ Mol Ther Nucleic Acids, 2023, 34:102047]	PubMed: 37869260
Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury [ Cell Rep, 2023, 42(9):113121]	PubMed: 37715952
Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury [ Cell Rep, 2023, 42(9):113121]	PubMed: 37715952
Coordinated inheritance of extrachromosomal DNA species in human cancer cells [ bioRxiv, 2023, 2023.07.18.549597]	PubMed: 37503111
Distinct mechanisms for sebaceous gland self-renewal and regeneration provide durability in response to injury [ bioRxiv, 2023, 2023.05.05.539454]	PubMed: 37205445

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.